493 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
GSK GlaxoSmithKline PLC $39.21 $97.25B Sell
Article Searches
3 Upcoming Readouts for Gilead Sciences You Don't Want to Miss https://www.fool.com/investing/2019/01/23/3-upcoming-readouts-for-gilead-sciences-you-dont-w.aspx?source=iedfolrf0000001 Jan 23, 2019 - Results from a few clinical trials reading out in 2019 could make it a year to remember.
Pharma Stock Roundup: Lilly to Buy Loxo for $8B, M&A in Focus at JP Morgan Meet http://www.zacks.com/stock/news/347005/pharma-stock-roundup-lilly-to-buy-loxo-for-%248b-ma-in-focus-at-jp-morgan-meet?cid=CS-ZC-FT-347005 Jan 11, 2019 - Lilly (LLY) is spending $8 billion to buy small cancer biotech Loxo Oncology. Big Pharma CEOs hint at spur in M&A activity in 2019.
New Strong Sell Stocks for January 11th http://www.zacks.com/stock/news/347000/new-strong-sell-stocks-for-january-11th?cid=CS-ZC-FT-347000 Jan 11, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
4 Pharma & Biotech Pipeline Areas to Keep an Eye on in 2019 http://www.zacks.com/stock/news/346884/4-pharma-biotech-pipeline-areas-to-keep-an-eye-on-in-2019?cid=CS-ZC-FT-346884 Jan 11, 2019 - Here we present four therapeutic areas whose pipeline developments are expected to garner a lot of interest in 2019.
Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting http://www.zacks.com/stock/news/346748/big-pharma-ceos-indicate-more-ma-deals-at-jp-morgan-meeting?cid=CS-ZC-FT-346748 Jan 10, 2019 - Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.
Crowded Cancer Space Triggers Big M&A Deals: More in Store? http://www.zacks.com/stock/news/346265/crowded-cancer-space-triggers-big-ma-deals-more-in-store?cid=CS-ZC-FT-346265 Jan 08, 2019 - Following two blockbuster merger and acquisition deals, a rise in M&A activity in the pharma space is likely led by consolidation in the cancer space.
GSK chief Walmsley not finished with business shakeup https://seekingalpha.com/news/3421141-gsk-chief-walmsley-finished-business-shakeup?source=feed_news_all Jan 07, 2019 - In an interview with CNBC's Jim Cramer, GlaxoSmithKline (GSK +0.7%) CEO Emma Walmsley says there are "tremendous opportunities" to improve operating performance, adding that the company will g
Merck Buys NASH Candidate, Keytruda Wins 5 Approvals in Japan http://www.zacks.com/stock/news/345648/merck-buys-nash-candidate-keytruda-wins-5-approvals-in-japan?cid=CS-ZC-FT-345648 Jan 04, 2019 - Merck (MRK) exercises option to in-license an insulin sensitizer from NGM Biopharmaceuticals for NASH and type II diabetes. Its key drug Keytruda snaps up five new label expansion nods in Japan.
Top Research Reports for Facebook, Wells Fargo & AT&T http://www.zacks.com/research-daily/201456/top-research-reports-for-facebook-wells-fargo-att?cid=CS-ZC-FT-201456 Jan 02, 2019 - Top Research Reports for Facebook, Wells Fargo & AT&T
Novartis (NVS) Benefits From New Drugs & Key Acquisitions http://www.zacks.com/stock/news/345148/novartis-nvs-benefits-from-new-drugs-key-acquisitions?cid=CS-ZC-FT-345148 Dec 31, 2018 - Novartis (NVS) gets a boost from strong performance of new drugs. Strategic acquisitions to foray into promising areas has also boosted investor sentiment.

Pages: 1234567891011...50

<<<Page 6>